Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Status:
Recruiting
Trial end date:
2024-03-20
Target enrollment:
Participant gender:
Summary
An open label, single/multiple dose exploratory clinical study to evaluate the safety,
efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen
receptor T cell in advanced solid tumor.